What Louisiana's new peptide law does and does not do
Louisiana Act 374 of 2026 took effect on 1 August 2026. It enacts a new section of the state's professions and occupations code, R.S. 37:23.5, and its operative effect is narrow: it limits what Louisiana's professional and occupational licensing boards may prohibit. It does not approve any substance, it does not displace federal law, and it does not alter the status of material sold for in-vitro laboratory research. Secondary coverage summarising the act as making peptides legal in Louisiana overstates it.
What does the statute actually provide?
Act 374 began as Senate Bill 253 of the 2026 Regular Session. The legislature's own bill record shows it signed by the governor on 22 May 2026 with an effective date of 1 August 2026.
Its substance is a prohibition directed at state boards rather than a grant of authority. A professional or occupational licensing board may not prohibit a health care provider who already holds prescriptive authority from providing peptides to patients where the material is shipped from an FDA-registered 503B outsourcing facility operating in compliance with 21 U.S.C. 353b, or from a 503A compounding pharmacy operating in compliance with 21 U.S.C. 353a and the applicable USP–NF chapters. A parallel provision bars boards from prohibiting a Louisiana-licensed pharmacist in a state-permitted pharmacy from compounding and dispensing peptides on the same compliance conditions. The bill as drafted also places a verification obligation on the prescriber regarding substances FDA has identified as not permissible for compounding.
Every one of those conditions is a reference outward to federal compounding law. The statute does not define which peptides qualify; it defers that question entirely to the federal framework.
Does this change anything at the federal level?
No, and the federal record has not moved. FDA announced on 30 April 2026, and published in the Federal Register on 1 May 2026 (91 FR 23431), a proposal not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List, on the stated basis that it did not identify a clinical need for outsourcing facilities to compound those substances from bulk given the availability of approved products. The comment period closed on 30 July 2026 and FDA has published no final determination. Separately, the Pharmacy Compounding Advisory Committee met on 23–24 July 2026 on nominated bulk substances for the 503A list; advisory committee recommendations are non-binding, and adding a substance to that list would require FDA rulemaking that has not occurred.
A state statute cannot supply the federal predicate. Where federal law does not permit a substance to be compounded, Act 374 does not make it permissible — it removes a layer of state licensing exposure that would otherwise sit on top.
What does it mean for laboratory suppliers?
Directly, nothing. Act 374 governs prescribers, pharmacists and the state boards that license them. Veridian Research supplies research-grade material for in-vitro laboratory research only, not for human or veterinary use, and that channel is not addressed by the statute in either direction.
The relevance is as an indicator. State legislatures are now legislating in a space where the federal record is unsettled, and divergence between the two produces exactly the kind of ambiguity that draws enforcement attention and raises documentation expectations across the supply chain.
What is checkable next?
Three things, each with a primary source: whether other states enact comparable licensing-board provisions in their 2026–2027 sessions; publication of FDA's final determination on the 503B notice in the Federal Register; and posting of PCAC minutes from the July meeting. None of the three had occurred as of 4 August 2026. Secondary trackers have run ahead of all three, and should not be read as the record.